The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r(-/-) mice. In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling. Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1R and GIP-R have been identified in brain regions involved in the regulation of appetite, satiety, food/energy intake and energy expenditure, which is consistent with the significant impact on body weight observed with incretin therapy.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The individual necessity of distinct GLP-1R neuron populations for the anorectic and weight loss effects of GLP-1RAs has now been claimed by multiple studies using various loss-of-function approaches in rodents (47, 50‐54, 69).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 9×
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“Physiologically, GLP-1 released from endocrine cells lining the gut acts peripherally (13, 42).”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 4×
“Given the well-known role of NTS-produced GLP-1 in appetite regulation, it is tempting to speculate that peripheral administration of GLP-1 or analogs activates NTS GLP-1–positive neurons that in turn reduce appetite (22, 23).”
InfluentialObesity is associated with hypothalamic injury in rodents and humans.
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59660 · Cited by 1,857
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“…analogs, like exenatide and lixisenatide, display a marked reduction of GE, which may contribute to short-term effects on food intake, while liraglutide and exenatide, formulated for slow release, have only a minor effect on GE, which then cannot be the mediator of the body weight effects (16, 17).”
Hypothalamic CART is a new anorectic peptide regulated by leptin
Kristensen, P., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., et al. (1998) · Nature · doi:10.1038/29993 · Cited by 1,282 · cited 1×
“…access to the brain and how they may affect the key neuronal pathways that regulate energy balance, such as the neuropeptide Y/agouti-related peptide (NPY/ AgRP) and proopiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons located in the arcuate nucleus (ARC) (7–11).”
Self-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction (31, 32).”
NPY/AgRP Neurons Are Essential for Feeding in Adult Mice but Can Be Ablated in Neonates
Luquet, S., Perez, F. A., Hnasko, T. S., & Palmiter, R. D. (2005) · Science · doi:10.1126/science.1115524 · Cited by 1,125
Research works printed but not linked: 1
- Astrup A, Rossner S, Van Gaal L. Effects of lirag- lutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. · DOI · Paper page
Cited by
Items 501–600 of 958
Effects of Bariatric Surgery on Energy Homeostasis
Li, W., & Richard, D. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.05.002 · Cited by 19
Merkel, R., Moreno, A., Zhang, Y., Herman, R. J., Nathan, J. B., Zeb, S., Rahematpura, S., Stecyk, K. S., Milliken, B. T., Hayes, M. R., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.026 · Cited by 17
Kim, K. K. (2019) · Korean Journal of Family Medicine · doi:10.4082/kjfm.19.0013 · Cited by 21
Chmielewski, A., Hübert, T., Descamps, A., Mazur, D., Daoudi, M., Ciofi, P., Fontaine, C., Caiazzo, R. J., Pattou, F. N., Prévot, V., et al. (2019) · Obesity · doi:10.1002/oby.22465 · Cited by 20
“Studies have suggested that circulating leptin (9), and possibly other metabolic hormones (19,20), enter the brain through the hypothalamic median eminence and that tanycytes, which are specialized but highly plastic ependymo-glial cells (21,22) that capture leptin from the bloodstream (9), act as a checkpoint along t…”
BackgroundGirges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Foll, C. L., & Lutz, T. A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190034 · Cited by 27
Patient initiation and maintenance of GLP-1 RAs for treatment of obesity
Patel, D., & Smith, A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1947796 · Cited by 16
Alsheikh, A., Alshehri, A., Alzahrani, S., Jammah, A. A., Alqahtani, F., Alotaibi, M., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01516-z · Cited by 16
“Because of the chemical structure of semaglutide, it is believed that receptors in the CNS provide the weight impact by allowing access to more parts of the nervous system [25].”
Chen, Y., Wang, L., Zhou, Y., Wang, Y., Qin, W., Wang, M., Liu, B., Tian, Q., Xu, H., Shen, H., et al. (2025) · Basic Research in Cardiology · doi:10.1007/s00395-025-01096-y · Cited by 18
“GLP-1 plays multiple roles, including regulating insulin secretion, controlling appetite, and modulating autonomic nervous system activity [11, 27].”
Dietary restriction in aging and longevity
Schmauck‐Medina, T., Lautrup, S., Francesco, A. D., Mitchell, S. J., Clemmensen, C., Partridge, L., Roth, G. S., Anderson, R. M., Mattison, J. A., de Cabo, R., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01091-5 · Cited by 28
Oh, H. S., Choi, M., Lee, T. S., An, Y., Park, E. J., Kim, T. H., Shin, S., & Shin, B. S. (2023) · Journal of Analytical Science & Technology · doi:10.1186/s40543-023-00382-5 · Cited by 20
Bombassaro, B., ARAUJO, E. P. D., & Velloso, L. A. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0082 · Cited by 23
Yada, T., Dezaki, K., & Iwasaki, Y. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00168.2025 · Cited by 16
Yabe, D., Kuwata, H., Usui, R., Kurose, T., & Seino, Y. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1045471 · Cited by 16
Pharmacological Interventions for Obesity: Current and Future Targets
Bocarsly, M. E. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0204-0 · Cited by 21
Parmila, K., Nakata, M., Zhang, B. Y., Otgon-Uul, Z., & Yada, T. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.199 · Cited by 16
Masuda, Y., Ohbayashi, K., & Iwasaki, Y. (2025) · Diabetology International · doi:10.1007/s13340-025-00819-9 · Cited by 17
Tongta, S., Sungkaworn, T., & Pathomthongtaweechai, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210974 · Cited by 21
“GLP-1 acts centrally by activating POMC neurons in the hypothalamic ARC to promote satiety while simultaneously inhibiting dopamine neurons in the VTA to reduce homeostatic hunger and decrease the food reward value [91–93].”
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
Pratley, R. E., Saeed, Z. I., & Casu, A. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001057 · Cited by 16
“pancreatitis seemingly associated with the use of exenatide were reported to the FDA through MedWatch (the US FDA Adverse Event Reporting System or FAERS) [19].”
Intestinal NAPE-PLD contributes to short-term regulation of food intake via gut-to-brain axis
Rastelli, M., Hul, M. V., Terrasi, R., Lefort, C., Régnier, M., Beiroa, D., Delzenne, N. M., Everard, A., Nogueiras, R., Luquet, S. H., et al. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00146.2020 · Cited by 17
Victorino, D. B., Nejm, M. B., Guimarães‐Marques, M., Scorza, F. A., & Scorza, C. A. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00374-5 · Cited by 19
Dischinger, U., Hasinger, J., Königsrainer, M., Corteville, C., Otto, C., Faßnacht, M., Hankir, M., & Seyfried, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.598843 · Cited by 19
Glucagon-like Peptide-1 Receptor Agonists
Jeon, J. Y., & Kim, H. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_14 · Cited by 16
FTO gene expression in diet-induced obesity is downregulated by Solanum fruit supplementation
Edeke, A. A., Nwodo, O. F. C., Assumpta, A. C., Orizu, U. N., Okoro, N. O., & Odiba, A. S. (2022) · Open Life Sciences · doi:10.1515/biol-2022-0067 · Cited by 16
Circulating GLP-1 in infants born small-for-gestational-age: breast-feeding versus formula-feeding
Díaz, M., Bassols, J., Sebastiani, G., López‐Bermejo, A., Ibáñez, L., & de Zegher, F. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.117 · Cited by 15
Abtahi, S., VanderJagt, H. L., & Currie, P. J. (2016) · Neuroreport · doi:10.1097/wnr.0000000000000650 · Cited by 15
Nonogaki, K., & Kaji, T. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.08.009 · Cited by 15
Wu, W., Sheng, K., Xu, X., Zhang, H., & Zhou, G. (2018) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2018.02.003 · Cited by 15
Charpentier, J., Waget, A., Klopp, P., Magnan, C., Cruciani‐Guglielmacci, C., Lee, S. J., Burcelin, R., & Grasset, E. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00348.2017 · Cited by 15
Sabbagh, M. N., Cummings, J. L., Ballard, C. G., van der Flier, W. M., Heneka, M. T., Holst, J. J., Knudsen, L. B., Salloway, S., Tansey, M. G., & Drucker, D. J. (2025) · Nature Aging · doi:10.1038/s43587-025-01029-3 · Cited by 17
“Both medicines are approved for the treatment of T2D and obesity 51 .”
Kumar, N., & D’Alessio, D. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac276 · Cited by 14
Stier, C. K., Koschker, A., Kim, M., Stier, R., Chiappetta, S., & Stein, J. M. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.05.009 · Cited by 17
Balapattabi, K., Yavuz, Y., Jiang, J., Deng, G., Mathieu, N. M., Ritter, M. L., Opichka, M. A., Reho, J. J., McCorvy, J. D., Nakagawa, P., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112935 · Cited by 14
Le, T. D. V., Liu, D., Besing, G.-L. K., Raghavan, R., Ellis, B. J., Ceddia, R. P., Collins, S., & Ayala, J. E. (2023) · eLife · doi:10.7554/elife.80944 · Cited by 16
“This suggests that Raptor phosphorylation at Ser 791 by PKA contributes to the weight loss effect of GLP-1R agonists but not other G s-targeting pharmacological agents such as setmelanotide.”
BackgroundSpezani, R., Marinho, T. D. S., Santos-Reis, T., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2023) · Peptides · doi:10.1016/j.peptides.2023.171138 · Cited by 17
Lu, Z., Yeung, C. K., Lin, G., Yew, D. T. W., Andrews, P. L. R., & Rudd, J. A. (2016) · Autonomic Neuroscience · doi:10.1016/j.autneu.2016.09.003 · Cited by 14
“Glucagon like peptide (GLP-1) is of particular interest because of its ability to regulate blood glucose in Type 2 diabetes, decrease appetite, reduce food intake and causeweight loss (Buse et al., 2013;Meier, 2012; Secher et al., 2014; van Bloemendaal et al., 2014).”
Ruska, Y., Szilvásy‐Szabó, A., Kővári, D., Kádár, A., Mácsai, L., Sinkó, R., Hrabovszky, E., Gereben, B., & Fekete, C. (2021) · Brain Structure and Function · doi:10.1007/s00429-021-02380-y · Cited by 13
MC4R biased signalling and the conformational basis of biological function selections
Liu, Z., & Hruby, V. J. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17441 · Cited by 17
Budin, A. J., Brown, W. A., MacCormick, A. D., Caterson, I. D., & Sumithran, P. (2025) · Obesity Reviews · doi:10.1111/obr.13927 · Cited by 18
Yang, M., Jia, M., Cai, M., Feng, X., Huang, L., & Yang, J. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06840-9 · Cited by 18
“It is primarily secreted by intestinal L cells in the periphery and by neurons in the nucleus of the solitary tract (NTS) in the CNS (Holst 2007; Secher et al. 2014).”
Semaglutide for adults living with obesity
Bracchiglione, J., Meza, N., Franco, J. V. A., Liquitay, C. M. E., Victoria Novik, A., Vargas, M. O., Lazcano, G., Poloni, D., Langlotz, F. R., Figuls, M. R. I., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015092.pub2 · Cited by 36
Mahadevan, A., Vosooghi, A., Arora, J. S., Kumar, R. S., Singh, G., Tsai, K. K., & Quandt, Z. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf703 · Cited by 16
Patil, M., Casari, I., Warne, L. N., & Falasca, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116245 · Cited by 12
Lavoie, O., Turmel, A., Mattoon, P., Desrosiers, W. J., Plamondon, J., Michael, N. J., & Caron, A. (2024) · Neuroendocrinology · doi:10.1159/000538716 · Cited by 12
“Such indirect inhibition has been documented in electrophysiological studies assessing the response of GABAergic NPY/AgRP neurons to GLP1R agonists [23 – 25].”
InfluentialKlausen, M. K., Kuzey, T., Pedersen, J. N., Justesen, S. K., Rasmussen, L. J. H., Knorr, U., Mason, G. F., Ekstrøm, C. T., Holst, J. J., Koob, G. F., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-086454 · Cited by 14
Integration of Glucagon-Like Peptide 1 Receptor Actions Through the Central Amygdala
Duran, M., Willis, J. R., Dalvi, N., Fokakis, Z. N., VIRKUS, S., & Hardaway, J. A. (2025) · Endocrinology · doi:10.1210/endocr/bqaf019 · Cited by 13
Jones, S., Hyde, A., & Davidson, T. L. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.05.001 · Cited by 18
“However, peripheral administration of GLP-1 analogues can reduce intake and body weigh in rats following subdiaphragmatic vagal deafferentation [91], indicating that GLP-1 acts directly at sites in the central nervous system (CNS) independent of vagal input [92].”
BackgroundModel, J. F. A., Lima, M. V., Ohlweiler, R., Sarapio, E., Vogt, É. L., Rocha, D. S., de Souza, S. K., & Vinagre, A. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119586 · Cited by 15
Zheng, H., Sigal, R. J., Coyle, D., Bai, Z., Johnston, A., Elliott, J., Hsieh, S., Kelly, S., Chen, L., Skidmore, B., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3515 · Cited by 18
Anti-obesity weight loss medications: Short-term and long-term use
Jeong, D., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120825 · Cited by 21
Yang, D., Hou, X., Yang, G., Li, M., Zhang, J., Han, M., Zhang, Y., & Liu, Y. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s380577 · Cited by 14
“In contrast, a relatively high glycemic status was observed after the application of central GLP-1R antagonists, suggesting that the activation of central GLP-1R is essential for glucose homeostasis.(76) Liraglutide, a GLP-1R agonist, can directly bind to GLP-1R on the cell membrane to activate the hypothalamic POMC n…”
BackgroundBiology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 22
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice
McMorrow, H. E., Cohen, A. B., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186652 · Cited by 12
“Prior studies have shown GLP-1 analogs inhibit AgRP neurons in slice preparations and modulate Agrp gene expression (21, 44), but they did not demonstrate an acute in vivo effect of peripherally administered GLP-1R agonist on AgRP neuron dynamics.”
InfluentialLambert, F., Guillon, E., Gatta‐Cherifi, B., CranioGLP1_FORCE Group, Soula, H., Poitou, C., & Faucher, P. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70216 · Cited by 12
“6,7 These mechanisms suggest potential interest in managing aHO.”
Campos, C., & Unger, J. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1971461 · Cited by 13
“appetite and hunger in the central nervous system (Figure 1) [46,47].”
BackgroundNPFF Decreases Activity of Human Arcuate NPY Neurons: A Study in Embryonic-Stem-Cell-Derived Model
Torz, L., Niss, K., Lundh, S. H., Rekling, J. C., Quintana, C. D., Frazier, S. E. D., Mercer, A. J., Cornea, A. M., Bertelsen, C., Gerstenberg, M. K., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063260 · Cited by 13
“Moreover, hALNs displayed action potentials and repetitive train behavior, demonstrating the ability of burst firing, which is a well-described electrophysiological characteristic for arcuate NPY neurons [46,47].”
BackgroundResearch progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
He, X., Zhao, W., Li, P., Zhang, Y., Li, G., Su, H., Lu, B., & Pang, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1483792 · Cited by 21
Current and emerging pharmacotherapies for obesity in Australia
HOCKING, S. L., Dear, A. E., & Cowley, M. A. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2017.07.002 · Cited by 14
Self-citationAnesten, F., Gasull, A. D., Richard, J. E., Farkas, I., Mishra, D., Taing, L., Zhang, F., POUTANEN, M. H., Pálsdóttir, V., Liposits, Z., et al. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12722 · Cited by 13
van Olst, N., Meiring, S., de Brauw, M., Bergman, J. J. G. H. M., Nieuwdorp, M., van der Peet, D. L., & Gerdes, V. E. A. (2020) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2020.03.003 · Cited by 13
Alexopoulou, F., Bech, E. M., Pedersen, S. L., Thorbek, D. D., Leurs, U., Rudkjær, L. C. B., Fosgerau, K., Hansen, H. H., Vrang, N., Jelsing, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05310-y · Cited by 14
Self-citationHaspula, D., & Cui, Z. (2023) · Cells · doi:10.3390/cells12131801 · Cited by 14
Just a Gut Feeling: Central Nervous Effects of Peripheral Gastrointestinal Hormones
Roth, C. L., & Doyle, R. P. (2017) · Endocrine development · doi:10.1159/000475734 · Cited by 12
Addressing Obesity in Clinical Gynecology Practice
Kahan, S. I., & Winston, G. J. (2018) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000334 · Cited by 14
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“…system (CNS) target engagement predominantly at circumventricular and periventricular-adjacent sites with limited penetration of the intact blood–brain barrier, including the area postrema and median eminence, with downstream recruitment of broader hindbrain and hypothalamic circuits 76,77,79,80 .”
Tinsley, I. C., Borner, T., Swanson, M. L., Chepurny, O. G., Doebley, S. A., Kamat, V., Sweet, I. R., Holz, G. G., Hayes, M. R., Jonghe, B. C. D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00185 · Cited by 11
RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis
Jamaluddin, A., & Gorvin, C. M. (2023) · Journal of Molecular Endocrinology · doi:10.1530/jme-23-0014 · Cited by 12
GLP-1 for Treating Obesity—Origin, History, and Evolution
Knudsen, L. B. (2024) · JAMA · doi:10.1001/jama.2024.18000 · Cited by 11
3D light-sheet fluorescence microscopy in preclinical and clinical drug discovery
Roostalu, U., Hansen, H. H., & Hecksher‐Sørensen, J. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104196 · Cited by 11
Self-citationA Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
“Blocking Arc GLP-1R signaling with Ex-9 attenuated the ano-rectic effects of peripheral liraglutide treatment, whereas with Ex-9 blockade directed toward the PVN, liraglutide maintained its anorectic effect (Secher et al. 2014).”
InfluentialCurrent understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists
Feng, J., & Jin, T. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0026 · Cited by 17
Insights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
Evaluation of VGF peptides as potential anti-obesity candidates in pre-clinical animal models
Dalbøge, L. S., Jacobsen, J. M., Mehrotra, S., Mercer, A. J., Cox, N., Liu, F., Bennett, C. M., Said, M. Y., Tang‐Christensen, M., Raun, K., et al. (2020) · Peptides · doi:10.1016/j.peptides.2020.170444 · Cited by 11
“GLP-1, leptin, and ghrelin were selected to validate the efficiency of the screen due to their well-establish actions in hypothalamic neurons [26-28].”
BackgroundSelf-citationTargeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors
Piper, N. B. C., Whitfield, E. A., Stewart, G. D., Xu, X., & Furness, S. G. B. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115115 · Cited by 11
Lu, Z., Yeung, C.-K., Lin, G., Yew, D. T. W., Andrews, P. L. R., & Rudd, J. A. (2017) · Neuropeptides · doi:10.1016/j.npep.2017.04.006 · Cited by 13
“, 1987), an integration of autonomic outflow that involves the NTS, hypothalamus, CeA, cingulate cortex (Saper, 2002), mechanisms of food intake that involves the AP, NTS, dorsal and ventral medial hypothalamus, arcuate nucleus (Alhadeff and Grill, 2014; Baggio et al., 2008; Secher et al., 2014; Shirazi et al., 2013),…”
InfluentialTrevaskis, J. L., Sacramento, C. B., Jouihan, H. A., Ali, S., Lay, J. E. L., Oldham, S. N., Bhagroo, N. V., Boland, B. B., Cann, J. A., Yuan, C., et al. (2017) · Diabetes · doi:10.2337/db16-0916 · Cited by 13
“As reported (26,27), following liraglutide treatment, c-Fos expression was increased in key hypothalamic and brainstem/medullary centers relevant for metabolic control including the paraventricular nucleus (Fig.”
BackgroundMethodKaineder, K., Birngruber, T., Rauter, G., Obermüller, B., Eichler, J., Münzker, J., Al-Zoughbi, W., Mautner, S., Torekov, S. S., Hartmann, B., et al. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.98 · Cited by 15
Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
Hansen, C. S., Frandsen, C. S., Fleischer, J., Vistisen, D., Holst, J. J., Tarnow, L., Knop, F. K., Madsbad, S., Andersen, H. U., & Dejgaard, T. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00242 · Cited by 11
Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years
Rose, F., Bloom, S. R., & Tan, T. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1646243 · Cited by 11
Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes
Ito, D., Iuchi, T., Kurihara, S., Inoue, I., Katayama, S., & Inukai, K. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2237w · Cited by 11
“On the other hand, recent studies have focused on the appetite suppressing effects of liraglutide exerted via the ventromedial nucleus of the hypothalamus [33, 34].”
BackgroundFarokhnia, M., Sheskier, M. B., Lee, M. R., Le, A. N., Singley, E., Bouhlal, S., Ton, T., Zhao, Z., & Leggio, L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.011 · Cited by 13
“Notably, GABA-B-mediated processes are involved in both peripheral secretion of these hormones, as well as the mechanisms through which they act in the central nervous system (Ataie et al., 2013; Braun et al., 2004; Cruz et al., 2013; Evans et al., 2014; Fulton et al., 2006; Gameiro et al., 2005; Guimond et al., 2014;…”
Fortin, S. M., Chen, J., & Hayes, M. R. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.112870 · Cited by 10
Zakaria, H., Alshehhi, S., Caccelli, M., Ozkan, C., Kattan, J., Jafaar, Z., Laborte, R., Aleabova, S., Almarzooqi, N., Hashemi, A., et al. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100283 · Cited by 11
“…pathways; they enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion under hyper-glycemic or euglycemic conditions, slow gastric emptying to prevent postprandial glucose spikes and decrease appetite and food intake, which collectively contribute to weight loss [8,9].”
BackgroundLee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00279-4 · Cited by 10
“[51, 52] Interestingly, GLP1-RA can impact food choices by promoting the selection of healthier, less energy-dense foods in human studies [53, 54].”
BackgroundWang, X.-Y., Liu, Y., Cao, L.-X., Li, Y.-Z., Wan, P., & Qiu, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-34070-6 · Cited by 12
Lee, J., & Kim, W. K. (2023) · Animals · doi:10.3390/ani13182975 · Cited by 10
“[92], they observed that GLP-1R restricts the synapses of NPY/AgRP neurons by influencing GABAergic neurons.”
BackgroundImpaired brain glucose metabolism in glucagon-like peptide-1 receptor knockout mice
Li, H., Fang, Y., Wang, D., Shi, B., & Thompson, G. J. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00343-w · Cited by 13
“Rodent studies revealed that administration of GLP-1R agonists to the central or peripheral nervous system can activate a subset of GLP – 1R – expressing neurons and produce weight loss [10, 11].”
BackgroundAa, B., Serova, M., Chashkina, M. I., Kosharnaia, R. S., Salpagarova, Z. K., Andreev, D. A., & Giverts, I. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.06 · Cited by 13
“9,10 These actions change eating behaviour: the anticipatory food reward for looking forward to eating certain (delicious) foods decreases, while consummatory food reward (the pleasure offered by eating) increases.”
The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies
Tonin, G., Eržen, S., Mlinarič, Z., Jurišić‐Eržen, D., Horvat, S., Kunej, T., & Klen, J. (2025) · Obesity Reviews · doi:10.1111/obr.13978 · Cited by 18
Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits
Hwang, E., Portillo, B., & Williams, K. W. (2025) · Endocrinology · doi:10.1210/endocr/bqaf125 · Cited by 10
Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats
Fang, J., Miller, P., & Grigson, P. S. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.11.012 · Cited by 13
Tolerance develops toward GLP-1 receptor agonists’ glucose-lowering effect in mice
Sedman, T., Krass, M., Rünkorg, K., Vasar, E., & Volke, V. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173443 · Cited by 12
Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetitePreprint
McMorrow, H. E., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.18.585583 · Cited by 10
Topography of the GLP-1/GLP-1 receptor system in the spinal cord of male mice
Ruska, Y., Csibi, A., Dorogházi, B., Szilvásy‐Szabó, A., Mohácsik, P., Környei, Z., Dénes, Á., Kádár, A., Puskár, Z., Hrabovszky, E., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65442-1 · Cited by 11
“The weight-reducing effects of GLP-1R agonists are primarily attributed to their direct action on GLP-1R-expressing neurons in the hypothalamus and brainstem, although the exact mechanisms still remain to be investigated 2,12,17–19 .”
BackgroundWen, J., Nadora, D., Bernstein, E., How-Volkman, C., Truong, A., Akhtar, M., Prakash, N. A., Puglisi, J. L., & Frezza, E. E. (2024) · Cureus · doi:10.7759/cureus.69008 · Cited by 21
Does Incretin Agonism Have Sustainable Efficacy?
Janket, S., Chatanaka, M. K., Sohaei, D., Tamimi, F., Meurman, J. H., & Diamandis, E. P. (2024) · Cells · doi:10.3390/cells13221842 · Cited by 11
Siriyotha, S., Anothaisintawee, T., Looareesuwan, P., Nimitphong, H., McKay, G. J., Attia, J., & Thakkinstian, A. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086424 · Cited by 13
“4 In addition, binding GLP-1 with its receptors in the central nervous system can increase satiety and decrease appetite, 5 6 which consequently promote weight loss.”
Chen, Q. H., Yang, Y., Xu, J., Wang, J., Fang, T., Yuan, Y., Wang, C., & Zhang, L. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.013 · Cited by 10
Metadata
- Authors
- Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Gubra (Denmark) (DK)
- Oregon National Primate Research Center (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-09-09
- Volume
- 124
- Issue
- 10
- Pages
- 4473-4488
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4215190
- OpenAlex
- W2014156217
- Cited by
- 961
- References
- 95
- Citations by year
- 2026: 100 · 2025: 126 · 2024: 123 · 2023: 85 · 2022: 77 · 2021: 93 · 2020: 56 · 2019: 63 · 2018: 62 · 2017: 65 · 2016: 52 · 2015: 53 · 2014: 5
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor, arcuate nucleus, weight loss, hypothalamus, proopiomelanocortin neurons, neuropeptide Y, agouti-related protein, GABAergic inhibition, circumventricular organs, GLP-1 analogues, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cocaine- and Amphetamine-Regulated Transcript Protein, Animals, Arcuate Nucleus of Hypothalamus, Body Weight, Disease Models, Animal, Electrophysiology, Hypothalamus, Male, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Paraventricular Hypothalamic Nucleus, Pro-Opiomelanocortin, Vagus Nerve, Weight Loss, Rats, Sprague-Dawley, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.